| Revenue growth | INR 3,373 Cr in FY26 |
|---|---|
| Margins | EBITDA margin improved from 5.4% to 18.6% |
| Demand visibility | Strong for insulin and anti-MRSA brands |
| Management confidence | High regarding Zaynich US FDA/CDSCO approvals |
Growth
51% YoY EBITDA growth; Income at INR 3,373 Cr. Emrok grew ~50%; Biotech business grew 27%.
Outlook
Launching Zaynich in US, India, Europe; doubling Human Insulin capacity; deepening biosimilars pipeline.
Risks
Antimicrobial resistance challenges, IP risks, and R&D process uncertainties.
Last quarter's promises, checked
Delivered
- Guided 20% Zaynich superiority → delivered 20% (= BEAT)
- Guided INR 1000 Cr QIP → delivered INR 1000 Cr (= BEAT)
- Guided EBITDA growth >60% → delivered 67% (= BEAT)
Partly delivered
- Guided Zaynich US launch FY26-27 → delivered US FDA approval (= PARTIAL)
- Guided 2x Insulin capacity in 24mo → delivered 2x scale-up (= PARTIAL)
Missed
- Guided Net Debt:Equity 0.01% → delivered 0.10% (= MISS)
- Guided Revenue INR 3033 Cr → delivered INR 3373 Cr (= BEAT)
Earnings Call filed with NSE, NSE: WOCKPHARMA. Summary written with AI assistance from the document.
Wockhardt Ltd: key numbers
- Share price
- ₹2,265.60
- Market cap
- ₹36,814 Cr
- Revenue (annual)
- ₹3,373 Cr
- Net profit (annual)
- ₹213.0 Cr
- P/E (TTM)
- 90.0×Sector 50.4×
- Promoter holding
- 49.08%+0.00% QoQ
- FII holding
- 7.23%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Wockhardt Ltd
All →Wockhardt Q1 FY27 Results: Turns Profitable, Net Profit ₹107 Cr
Wockhardt Ltd reported revenue from operations of ₹929 Cr (+25.9% YoY) and net profit of ₹107 Cr for Q1 FY27.
- Key figure
- Net profit ₹107 Cr
Wockhardt Earnings Call: Key Takeaways
Wockhardt reports FY26 revenue of ₹3,373cr with 51% EBITDA growth. Strategy focuses on novel antibiotic 'Zaynich', recently US FDA approved, and diabetes biosimilars to drive future scaling.
Wockhardt Q4 FY26 Results: Turns Profitable, Net Profit ₹164 Cr
Wockhardt Ltd reported revenue from operations of ₹965 Cr (+29.9% YoY) and net profit of ₹164 Cr for Q4 FY26.
- Key figure
- Net profit ₹164 Cr